LPCAT1 as a prognostic biomarker and risk indicator for hepatocellular carcinoma: insights into genes related to lipid metabolism

Background Hepatocellular carcinoma (HCC) is a lethal malignancy. Lipid metabolic reprogramming influences therapy response, but its prognostic value is undefined. Methods From TCGA and GEO data, we derived an 8-gene lipid metabolism-related risk score (LMrisk) via LASSO regression. Its associations with tumor immunity and drug sensitivity were analyzed. The lead gene, LPCAT1 , was functionally assessed in vitro . Results The LMrisk signature robustly stratified patient survival in both cohorts. Integrated analysis identified LPCAT1 as a hub gene. Its overexpression in HCC cells potently enhanced proliferation, migration, and invasion. Conclusion LPCAT1 is a vital prognostic biomarker and putative therapeutic target in HCC.